Last updated 23 days ago

Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

84 patients around the world
Available in Chile, United States
The study duration per participant will be up to 116 weeks.
Sanofi
1Research sites
84Patients around the world

This study is for people with

Hidradenitis suppurativa

Requirements for the patient

To 70 Years
All Gender

Medical requirements

Sites

Clínica Dermacross S.A. - Vitacura - Santiago
Clínica Dermacross S.A. - Vitacura - Santiago
Recruiting
Av. Manquehue Norte 2051 C, Vitacura, Metropolitana, 7640881
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy